How a malaria parasite is evading treatment

Plasmodium parasite
infecting a red blood cell
Image from St. Jude
Children’s Research Hospital
New research has revealed mutations that help the malaria parasite Plasmodium falciparum evade treatment. Researchers used whole-genome analyses and chemogenetics to identify drug targets and resistance genes in cell lines of P falciparum that are resistant to antimalarial compounds. The group’s work confirmed previously known mutations that contribute to the parasite’s resistance but also revealed new targets that may deepen our understanding of the parasite’s underlying biology. [Read Article]

Emicizumab still available despite legal issues

Emicizumab (Hemlibra)
Photo from Business Wire
The Roche Group has issued a statement reassuring the US hemophilia community that legal issues are not affecting patient access to emicizumab (Hemlibra), at least for the time being. Emicizumab is a bispecific factor IXa- and factor X-directed antibody approved in the US as routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children who have hemophilia A and factor VIII (FVIII) inhibitors. The Roche Group—which consists of Genentech in the US, Chugai in Japan, and Roche in the rest of the world—said emicizumab is still available for these patients, despite a legal battle with Baxalta, a wholly owned subsidiary of Shire. [Read Article]

Generic bortezomib available in US

Bortezomib for Injection
Photo from Business Wire
Fresenius Kabi has introduced its generic version of Velcade, Bortezomib for Injection, to the US market. This is the first intravenous alternative to Velcade available in the US. Bortezomib for Injection is available as a single dose vial containing 3.5 mg of lyophilized powder. The product is approved to treat patients with multiple myeloma and patients with mantle cell lymphoma who have received at least 1 prior therapy. [Read Article]